Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Cerilliant
Mallinckrodt
Citi
Merck
QuintilesIMS
Federal Trade Commission
Johnson and Johnson
Harvard Business School

Generated: December 19, 2018

DrugPatentWatch Database Preview

RELISTOR Drug Profile

« Back to Dashboard

Which patents cover Relistor, and when can generic versions of Relistor launch?

Relistor is a drug marketed by Salix Pharms and Salix Pharms Inc and is included in two NDAs. There are eleven patents protecting this drug and three Paragraph IV challenges.

This drug has one hundred and twelve patent family members in thirty-six countries.

The generic ingredient in RELISTOR is methylnaltrexone bromide. There are three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the methylnaltrexone bromide profile page.

Drug patent expirations by year for RELISTOR
Generic Entry Opportunity Date for RELISTOR
Generic Entry Dates for RELISTOR*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SOLUTION;SUBCUTANEOUS
Generic Entry Dates for RELISTOR*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for RELISTOR
Drug ClassOpioid Antagonist
Mechanism of ActionOpioid Antagonists
Synonyms for RELISTOR
(1S,5R,13R,17S)-4-(CYCLOPROPYLMETHYL)-10,17-DIHYDROXY-4-METHYL-14-OXO-12-OXA-4-AZAPENTACYCLO[9.6.1.0(1),(1)(3).0?,(1)?.0?,(1)?]OCTADECA-7(18),8,10-TRIEN-4-IUM
(1S,5R,13R,17S)-4-(CYCLOPROPYLMETHYL)-10,17-DIHYDROXY-4-METHYL-14-OXO-12-OXA-4-AZAPENTACYCLO[9.6.1.0(1),(1)(3).0?,(1)?.0?,(1)?]OCTADECA-7(18),8,10-TRIEN-4-IUM BROMIDE
(4R,4aS,7aR,12bS)-3-(cyclopropylmethyl)-4a,9-dihydroxy-3-methyl-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-3-ium-7-one
(5|A)-17-(Cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-17-methyl-6-oxomorphinanium Bromide
1356447-13-6
17-(Cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinanium-6-one
17-(cyclopropylmethyl)-4,5a-epoxy-3,14-dihydroxy-17-methyl-6-oxomorphinanium bromide
17-(Cyclopropylmethyl)-4,5alpha-epoxy-3,14-dihydroxy-17-methyl-6-oxomorphinanium
3844AH
73232-52-7
77061-EP2305652A2
77061-EP2308509A1
83387-25-1
AKOS015896214
AN-37324
BDBM50278337
C21H26NO4.Br
CHEBI:136007
CHEMBL1186579
CHEMBL1201770
CHEMBL470617
CHIR-01020
CS-0762
CTK3E8491
D03YVO
D06618
D0A6EE
GTPL7563
HY-75766
I06-1616
IFGIYSGOEZJNBE-KNLJMPJLSA-N
JVLBPIPGETUEET-GAAHOAFPSA-O
Methylnaltrexone
Methylnaltrexone (Bromide)
Methylnaltrexone bromide
Methylnaltrexone bromide (JAN/USAN)
Methylnaltrexone bromide, >=97% (HPLC)
Methylnaltrexone bromide, United States Pharmacopeia (USP) Reference Standard
Methylnaltrexonium
MNTX
MNTX-302
MOA-728
Morphinanium, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-17-methyl-6-oxo-, (5alpha)-
MRZ 2663BR
MRZ-2663BR
N-Cyclopropylmethyl-noroxymorphone Methobromide
N-Methyl Naltrexone Bromide
N-Methylnaltrexone
N-Methylnaltrexone Bromide
Naltrexone MB
Naltrexone methobromide
Naltrexone Methyl Bromide
ONO-3849
PL008834
PL071389
Quaternary ammonium naltrexone
Relistor (TN)
SCHEMBL2798188
SCHEMBL49356
ST51053157
W-5330
ZINC5764759

US Patents and Regulatory Information for RELISTOR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Salix Pharms Inc RELISTOR methylnaltrexone bromide TABLET;ORAL 208271-001 Jul 19, 2016 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Salix Pharms Inc RELISTOR methylnaltrexone bromide TABLET;ORAL 208271-001 Jul 19, 2016 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Salix Pharms RELISTOR methylnaltrexone bromide SOLUTION;SUBCUTANEOUS 021964-002 Sep 27, 2010 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for RELISTOR

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Salix Pharms RELISTOR methylnaltrexone bromide SOLUTION;SUBCUTANEOUS 021964-002 Sep 27, 2010 ➤ Try a Free Trial ➤ Try a Free Trial
Salix Pharms Inc RELISTOR methylnaltrexone bromide TABLET;ORAL 208271-001 Jul 19, 2016 ➤ Try a Free Trial ➤ Try a Free Trial
Salix Pharms RELISTOR methylnaltrexone bromide SOLUTION;SUBCUTANEOUS 021964-001 Apr 24, 2008 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for RELISTOR
Drugname Dosage Strength RLD Date
➤ Subscribe Tablets 150 mg ➤ Subscribe ➤ Try a Free Trial
➤ Subscribe Injection 8 mg/0.4 mL ➤ Subscribe ➤ Try a Free Trial
➤ Subscribe Injection 12 mg/0.6 mL ➤ Subscribe ➤ Try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Cerilliant
Mallinckrodt
Citi
Merck
QuintilesIMS
Federal Trade Commission
Johnson and Johnson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.